Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 1300 results for heart OR cardi* OR arrythmia

  1. Physical health of people in prison (NG57)

    This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

  2. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence (CG115)

    This guideline covers identifying, assessing and managing alcohol-use disorders (harmful drinking and alcohol dependence) in adults and young people aged 10 to 17 years. It aims to reduce harms (such as liver disease, heart problems, depression and anxiety) from alcohol by improving assessment and setting goals for reducing alcohol consumption.

  3. KODEX-EPD for cardiac imaging during ablation of arrhythmias (MIB260)

    NICE has developed a medtech innovation briefing (MIB) on KODEX-EPD for cardiac imaging during ablation of arrhythmias .

  4. The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation

  5. CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)

    NICE has developed a medtech innovation briefing (MIB) on CytoSorb for reducing risk of bleeding during cardiac surgery .

  6. Published

    The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.

  7. VA ECMO for postcardiotomy cardiogenic shock in adults (IPG810)

    Evidence-based recommendations on venoarterial extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults. This involves using an artificial lung to oxygenate the blood outside the body.

  8. Stage 5: discharge and transferring care

    Our guidance helps you hand over care and ensure people are safely transitioned out of the virtual ward environment.

  9. Hip fracture: management (CG124)

    This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.

  10. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

  11. Off-pump minimal access mitral valve repair by artificial chordae insertion to treat mitral regurgitation

    In development Reference number: GID-IPG10216 Expected publication date:  25 February 2026

  12. Delirium: prevention, diagnosis and management in hospital and long-term care (CG103)

    This guideline covers diagnosing and treating delirium in people aged 18 and over in hospital and in long-term residential care or a nursing home. It also covers identifying people at risk of developing delirium in these settings and preventing onset. It aims to improve diagnosis of delirium and reduce hospital stays and complications.

  13. Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

    This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

  14. Tirzepatide for managing overweight and obesity (TA1026)

    Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.